ClinicalTrials.gg
Not yet recruitingNCT06920316DEFIB-MASLDUpdated Apr 9, 2025

Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

A Phase 4 interventional study of Gro Health digital application in Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by St. George's Hospital, London. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by St. George's Hospital, London · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom — 17 open to participants now, 27 under way, 9 of them phase 3. Non-alcoholic Fatty Liver Disease · United Kingdom.

Planned enrollment
53rd of 101
100 · median 104
Started
2025
with 5 others
Phase 4
4 of 122
2 open now
Primary completion
2027-05
later than 11 of 26 live
Registered
117th of 122
by date

Among the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, this one is the 53rd largest by planned enrollment of the 101 interventional ones that give a count, is one of 6 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 11 of the 26 other live ones, and was the 117th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

17 of the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, or all of them as a file.
02

Study summary

Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD)

Objective:

This study aims to assess whether a digital application called Gro Health can help patients with MASLD and significant liver fibrosis reduce their liver stiffness. Liver stiffness is a measure of liver health and fibrosis. The study will also investigate the impact of this intervention on weight, body measurements, liver health markers, and overall quality of life.

Background:

MASLD is a liver condition linked to metabolic issues such as obesity and diabetes. It is a common cause of liver-related complications and can lead to severe liver damage. Lifestyle changes, like improved diet and exercise, are key to managing MASLD, but achieving these changes can be challenging for many patients. Digital tools like the Gro Health app may provide personalized and accessible support to improve outcomes.

Study Design:

This is a randomized controlled trial involving 100 participants with MASLD and significant fibrosis. Participants will be assigned to either the intervention group (using the Gro Health app) or a control group (receiving standard care). The study will take place at a single site over 12 months.

Intervention:

Participants in the intervention group will use the Gro Health app, which offers personalized calorie and activity goals, a food diary, over 1,000 Mediterranean diet recipes, and educational resources. They will also receive a smartwatch to track steps and physical activity. The app includes a feature allowing researchers to monitor participants' engagement and provide encouragement.

Eligibility:

Adults aged 18 or older with a diagnosis of MASLD and a liver stiffness measurement of 8 kPa or higher are eligible. Key exclusions include alcohol consumption over 14 units/week, a BMI over 40, or certain other liver diseases or medications.

Outcomes:

The primary outcome is a reduction in liver stiffness after six months. Secondary outcomes include changes in weight, BMI, body fat percentage, liver enzymes, cholesterol, and quality of life. Additional data on app usage, physical activity, and dietary habits will also be collected for the intervention group.

Potential Impact:

If successful, this study will provide evidence that digital tools can help improve liver health and overall well-being in patients with MASLD, offering a scalable solution for healthcare systems.

03

Conditions studied

  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Keywords

  • Non-alcoholic Fatty Liver Disease
  • Fatty liver
  • Digital health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years and over
  • Diagnosis of MASLD made by a hepatologist
  • Vibration-Controlled Transient Elastography (VCTE) (FibroScan) liver stiffness measurement (LSM) 8 kPa and above
  • Able to provide written consent
  • Own a smartphone with data plan

Exclusion criteria

Exclusion Criteria:

  • Alcohol consumption >14 units/week
  • >40
  • Liver disease due to: Alcohol including MASLD with increased alcohol intake (MetALD), Any viral hepatitis, and cholestatic aetiologies including, but not limited to, primary biliary cholangitis and primary sclerosing cholangitis, Hereditary aetiologies including, but not limited to, haemachromatosis, Wilson's disease, alpha-1-antitrypsin deficiency
  • Currently under investigation for cancer or receiving treatment for active cancer
  • Myocardial infarction within last 6 months or uncontrolled cardiovascular disease
  • Pregnant or planning
  • Currently or due to be taking any of the following drugs: GLP-1/GIP agonists, Systemic high dose for >6 weeks, Tamoxifen, Amiodarone, Methotrexate, Lomitapide, Valproate, Irinotecan, 5-Fluoruracil
  • Currently using or enrolled in any other lifestyle intervention application or weight loss programme
  • Undergone or due to undergo bariatric surgery including bariatric endoscopic procedures
  • Any other intercurrent illness that is either life-threatening or of clinical significance such that it might limit compliance with study procedures, in the Investigator's opinion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Gro Health Application

    The Gro Health digital application is a personalised treatment platform proven to support sustainable weight loss. It is non-MHRA regulated as MASLD is within the device's UKCA/CE UKNI/CE marked indication. Gro Health reports 7% weight loss at 52 weeks in patients with Type 2 Diabetes Mellitus. We can set up the application so patients follow a Mediterranean diet. Over 1000 recipes of different cuisines will be available, along with weekly diet plans and shopping lists. Based on the patient's body mass index, daily calories and macronutrient targets will be calculated in line with the Mediterranean diet. Aerobic exercise can be tracked by daily step count linked by compatible smartwatches and smartphones. Physical activity can also be logged manually. Gro Health provides educational videos on aerobic and resistance exercise, along with 'follow along' videos of exercises for patients. These videos range from ones for beginners to those who have more experience with exercise.

    Device: Gro Health digital application

  • No intervention
    Standard of Care

    If randomised to this arm, participants will not receiving any additional intervention beyond their usual clinical care for their condition.

Interventions

  • DeviceGro Health digital application

    The Gro Health digital application is a personalised treatment platform proven to support sustainable weight loss. It is non-MHRA regulated as MASLD is within the device's UKCA/CE UKNI/CE marked indication. Gro Health reports 7% weight loss at 52 weeks in patients with Type 2 Diabetes Mellitus. We can set up the application so patients follow a Mediterranean diet. Over 1000 recipes of different cuisines will be available, along with weekly diet plans and shopping lists. Based on the patient's body mass index, daily calories and macronutrient targets will be calculated in line with the Mediterranean diet. Aerobic exercise can be tracked by daily step count linked by compatible smartwatches and smartphones. Physical activity can also be logged manually. Gro Health provides educational videos on aerobic and resistance exercise, along with 'follow along' videos of exercises for patients. These videos range from ones for beginners to those who have more experience with exercise.

06

What researchers measure

Primary outcomes

  1. The primary outcome measure is change in liver stiffness measurement at 6 months compared to baseline

    The primary outcome measure is change in liver stiffness measurement (LSM) at 6 months compared to baseline. LSM is measured in kPa. Vibration controlled transient elastography (VCTE) has been validated as a measure of fibrosis across a wide spectrum of chronic liver diseases including MASLD. Whilst liver histology remains the gold standard for fibrosis staging, and magnetic resonance imaging and elastography for non-invasive hepatic lipid quantification and fibrosis respectively, both techniques are largely limited by being time consuming and expensive. VCTE provides multiple advantages of low cost, short procedure time, immediate result availability, good reproducibility and the ability to be performed in an outpatient setting. Studies have shown that LSM has good accuracy for liver-related events and mortality. Change in LSM has been shown to correlate with the risk of liver-related events and death.

    Time frame: 6 months

Secondary outcomes

  1. Weight in kilograms - To compare the effect of a digital application based lifestyle intervention to standard of care on weight

    Baseline weight in kilograms will be taken at day 0 on calibrated hospital scales in clinic from all study participants. A formal weight will be taken at all hospital clinic appointments and at 26 weeks and at the end of the intervention period. Only weights taken on the calibrated hospital scales will be used for analysis.

    Time frame: 6 and 12 months

  2. Percentage weight loss - To compare the effect of a digital application based lifestyle intervention to standard of care on percentage weight loss

    Baseline weight in kilograms will be taken at day 0 on calibrated hospital scales in clinic from all study participants. A formal weight will be taken at all hospital clinic appointments and at 26 weeks and at the end of the intervention period. Only weights taken on the calibrated hospital scales will be used for analysis.

    Time frame: 6 and 12 months

  3. Height in metres

    Height in metres will be taken at baseline for the use in BMI calculation as stated for BMI outcome

    Time frame: baseline

  4. Body mass index - To compare the effect of a digital application based lifestyle intervention to standard of care on BMI

    Baseline weight in kilograms will be taken at day 0 on calibrated hospital scales in clinic from all study participants. Baseline height will be taken at day 0 only. A formal weight will be taken at all hospital clinic appointments and at 26 weeks and at the end of the intervention period. Only weights taken on the calibrated hospital scales will be used for analysis.

    Time frame: 6 and 12 months

  5. Body fat percentage - To compare the effect of a digital application based lifestyle intervention to standard of care on body fat percentage

    Measured at baseline, 26 weeks and at the end of the intervention period using Withings smart scale

    Time frame: 6 and 12 months

  6. Controlled Attenuation Parameter - To compare the effect of a digital application based lifestyle intervention to standard of care on CAP.

    CAP is a measure of liver fat taken by Vibration Controlled Transient Elastography (also known as Fibroscan). Baseline CAP will be taken on day 0 using FibroScan machine by a trained operator who is not involved in the trial from all study participants. A reading will be taken at 26 weeks and at the end of the intervention period.

    Time frame: 6 and 12 months

  7. Spleen stiffness measurement - To compare the effect of a digital application based lifestyle intervention to standard of care on SSM

    Spleen stiffness measurement is measured by vibration controlled transient elastography (also known as Fibroscan) and indicates spleen scarring. Baseline SSM will be taken on day 0 using FibroScan machine by a trained operator who is not involved in the trial from all study participants. A reading will be taken at 26 weeks and at the end of the intervention period.

    Time frame: 6 and 12 months

  8. To compare the effect of a digital application based lifestyle intervention to standard of care on the following blood parameters: alanine transaminase ALT, aspartate aminotransferase AST, HbA1c

    Concentration of ALT, AST, HbA1c in blood samples will be taken on day 0, 26 weeks and at the end of the intervention period from all participants if not taken within the last 3 months

    Time frame: 6 and 12 months

  9. To compare the effect of a digital application based lifestyle intervention to standard of care on the following blood parameters: total cholesterol, low-density lipoprotein cholesterol LDL, high-density lipoprotein cholesterol HDL, triglycerides

    Concentration of total cholesterol, LDL, HDL and triglycerides in blood samples will be taken on day 0, 26 weeks and at the end of the intervention period from all participants if not taken within the last 3 months.

    Time frame: 6 and 12 months

  10. Waist and hip circumference - To compare the effect of a digital application based lifestyle intervention to standard of care on these measurements

    Baseline waist and hip circumference will be measured on day 0 using a tape measure in centimetres at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest as recommended by the WHO from all study participants. A measurement will be taken at 26 weeks and at the end of the intervention period.

    Time frame: 6 and 12 months

  11. Systolic blood pressure - To compare the effect of a digital application based lifestyle intervention to standard of care on blood pressure

    Baseline systolic blood pressure will be taken on day 0 from all study participants. A reading will be taken at 26 weeks and the end of the intervention period using a calibrated electronic sphygmomanometer.

    Time frame: 6 and 12 months

  12. 16. Echosens Agile 3+ score - composite score comprising LSM, ALT, AST, platelets, age, gender, diabetic status

    Agile 3+ score will be calculated from baseline LSM, ALT, AST, platelets, age, gender and diabetic status and again calculated using the same parameters taken at 26 weeks and at the end of the intervention period.

    Time frame: 6 and 12 months

  13. Health-related Quality of Life assessment - EuroQol EQ-5D-5L to compare the effect of a digital application based lifestyle intervention to standard of care on these

    Health-related Quality of Life will be measured using the EuroQol EQ-5D-5L on day 0, 26 weeks and at the end of the intervention by all participants.

    Time frame: 6 and 12 months

  14. Health-related Quality of Life assessment - Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH)) - To compare the effect of a digital application based lifestyle intervention to standard of care on these

    Health-related Quality of Life will be measured using the Chronic Liver Disease Questionnaire for Non-alcoholic Steatohepatitis (CLDQ-NASH) on day 0, 26 weeks and at the end of the intervention by all participants.

    Time frame: 6 and 12 months

  15. Hospital Anxiety and Depression Scale (HADS) - To compare the effect of a digital application based lifestyle intervention to standard of care on HADS

    Hospital Anxiety and Depression Scale will be measured on day 0, 26 weeks and at the end of the intervention period by all participants

    Time frame: 6 and 12 months

  16. Number of patients with improvement in liver stiffness measurement LSM - To compare the effect of a digital application based lifestyle intervention to standard of care on number of patients with improvement in LSM

    The total number of patients with improvement in LSM in each group

    Time frame: 6 and 12 months

  17. Liver stiffness measurement - same at primary outcome measure, but at 12 rather than 6 months

    The primary outcome measure is change in liver stiffness measurement (LSM) at 6 months compared to baseline. This secondary outcome is that same measure but at 12 months to see if results are sustained. LSM is measured in kPa. VCTE has been validated as a measure of fibrosis across a wide spectrum of chronic liver diseases including MASLD. Whilst liver histology remains the gold standard for fibrosis staging, and magnetic resonance imaging and elastography for non-invasive hepatic lipid quantification and fibrosis respectively, both techniques are largely limited by being time consuming and expensive. VCTE provides multiple advantages of low cost, short procedure time, immediate result availability, good reproducibility and the ability to be performed in an outpatient setting. Studies have shown that LSM has good accuracy for liver-related events and mortality. Change in LSM has been shown to correlate with the risk of liver-related events and death.

    Time frame: 12 months

  18. Assess the frequency of digital lifestyle application interaction

    Gro Health can provide data of individual patient's application usage in the form of total number of 'application openings'. In the intervention group, we would assess whether the participants with more app openings have a greater improvement in their VCTE LSM.

    Time frame: 12 months

  19. Assess the change in daily step count

    In the intervention group, daily step count electronically recorded by compatible smartwatch. Measure mean weekly step count and how this changes over the 12 month period.

    Time frame: 12 months

  20. Assess the change in amount and type of physical activity

    In the intervention group, in addition to daily step count, physical activity can be manually logged by patient (time and date of activity, type of activity and activity duration). Measure weekly total minutes of physical activity and how this changes over the 12 month period.

    Time frame: 12 months

  21. Assess the change in self-recorded weights

    In the intervention group, we would assess the trend in weight loss over the 12 month period

    Time frame: 12 months

  22. Assess the frequency of food diary usage

    In the intervention group, we would assess how frequently participants log food and how this changes over time

    Time frame: 12 months

  23. Assess the interaction with educational content

    Percentage of total educational content reviewed by 12 months. Assess if there is a correlation between amount of educational content reviewed and if this leads to a greater reduction in VCTE LSM.

    Time frame: 12 months

  24. Number of personalised messages sent to participant over 12 month period

    In the intervention group, personalised messages will be sent at least monthly and also ad hoc. We would assess whether the number of messages correlates with change in VCTE LSM.

    Time frame: 12 months

  25. Total minutes of telephone calls to participant over 12 month period

    In the intervention group, telephone calls will be made to participants at 1 week and then ad hoc. We would assess whether the number of minutes correlates with change in VCTE LSM.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for May 2027, 24 months later.

Of 41 non-industry phase 4 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 24 months is close to that.

Counting every sponsor, half of 44 studies reached it within 25 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Apr 9, 2025
StartEst.
May 2025
Primary completionEst.
May 2027
CompletionEst.
Sep 2027
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06920316
Lead sponsor
St. George's Hospital, London
Responsible party
Caroline Gosson (Principal Investigator, Hepatology Clinical Research Fellow, St. George's Hospital, London) — Principal investigator
First posted
Apr 9, 2025
Start date
May 2025 (estimated)
Primary completion
May 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Apr 9, 2025

Study contacts

Caroline Gosson, MBBS
Contact
caroline.gosson@stgeorges.nhs.uk
+4475902577755

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion